{"entity":{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","aka":[],"tldr":"Physician who directs IQWiG, the German institute that produces the benefit assessments underpinning cancer drug pricing and coverage decisions.","summary":"Dr. med. Thomas Kaiser is Director of the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne. He previously headed IQWiG's Drug Assessment department and has been a central figure in Germany's early benefit assessment (AMNOG) process for new medicines, including oncology drugs. He publishes on evidence standards, surrogate endpoints and health technology assessment methodology.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.iqwig.de/ueber-uns/struktur-des-instituts/institutsleitung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaiser+T%5BAuthor%5D+IQWiG"}],"tags":["leadership","health technology assessment","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["g-ba-iqwig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director (Institutsleiter), IQWiG","institutionId":"g-ba-iqwig","specialisms":["Health technology assessment","Evidence-based medicine","Drug benefit assessment"],"profiles":[{"label":"Institution profile","url":"https://www.iqwig.de/ueber-uns/struktur-des-instituts/institutsleitung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaiser+T%5BAuthor%5D+IQWiG"}],"papers":[{"title":"Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung","journal":"Das Gesundheitswesen","year":2022,"doi":"10.1055/a-1926-6818"}],"orcid":"0000-0003-0795-538X"},"route":"/people/thomas-kaiser/","neighbours":{"institution":[{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/"}]}}